Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 10, 2012 - Issue 6
Submit an article Journal homepage
15
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Should HDL cholesterol levels be the primary target of cardiovascular disease risk assessment and therapy?

Avishay Elis Department of Medicine D, Meir Medical Center, Israel and Sackler Faculty of Medicine, Tel Aviv University, Kfar Saba 44281, Tel Aviv, Israel. [email protected]
Pages 675-677 | Published online: 10 Jan 2014

References

  • Grundy SM, Cleeman JI, Merz CN et al.; National Heart, Lung, and Blood Institute American College of Cardiology Foundation American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2), 227–239 (2004).
  • Catapano AL, Reiner Z, De Backer G et al.; Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)ESC Committee for Practice Guidelines 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217(Suppl. 1), S1–S44 (2011).
  • Ross R. Atherosclerosis – an inflammatory disease. N. Engl. J. Med. 340(2), 115–126 (1999).
  • Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256(20), 2823–2828 (1986).
  • Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am. J. Med. 76(2A), 4–12 (1984).
  • Assmann G, Schulte H, Cullen P. New and classical risk factors – the Münster heart study (PROCAM). Eur. J. Med. Res. 2(6), 237–242 (1997).
  • Jones PH, Davidson MH, Stein EA et al.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92(2), 152–160 (2003).
  • The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251(3), 351–364 (1984).
  • Guyton JR. Effect of niacin on atherosclerotic cardiovascular disease. Am. J. Cardiol. 82(12A), U18–U23; discussion U39–U41 (1998).
  • Buchwald H, Varco RL, Boen JR et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch. Intern. Med. 158(11), 1253–1261 (1998).
  • Nissen SE, Tuzcu EM, Schoenhagen P et al.; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291(9), 1071–1080 (2004).
  • Nissen SE, Nicholls SJ, Sipahi I et al.; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295(13), 1556–1565 (2006).
  • Elis A, Zhou R, Stein EA. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Am. J. Cardiol. 108(2), 223–226 (2011).
  • Kastelein JJ, Akdim F, Stroes ES et al.; ENHANCE Investigators. Effect of the combination of ezetimibe and simvastatin versus monotherapy simvastatin on arterial intima-media thickness in familial hypercholesterolemia (ENHANCE): a randomized controlled trial. N. Engl. J. Med. 358, 1431–1443 (2008).
  • Stein EA. After ENHANCE: is more LDL cholesterol lowering even better? Clin. Chem. 54(6), 940–942 (2008).
  • Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8(4), 222–232 (2011).
  • Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124(Suppl.), S11–S20 (1996).
  • Barter P, Gotto AM, LaRosa JC et al.; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357(13), 1301–1310 (2007).
  • Elis A, Pereg D, Froom P, Lishner M, Segev D, Hermoni D. HDL-C levels and revascularization procedures in coronary heart disease patients treated with statins to target LDL-C levels. Clin. Cardiol. 34(9), 572–576 (2011).
  • Keech A, Simes RJ, Barter P et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849–1861 (2005).
  • Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102(1), 21–27 (2000).
  • Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258(2), 94–114 (2005).
  • Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth. J. Med. 62(7), 229–234 (2004).
  • Yadav R, Kwok S, Ammori BJ, Issa B, Soran H. Safety and tolerability of extended-release niacin with laropiprant. Expert Opin. Drug Saf. 11(1), 151–159 (2012).
  • Villines TC, Stanek EJ, Devine PJ et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J. Am. Coll. Cardiol. 55(24), 2721–2726 (2010).
  • Boden WE, Probstfield JL, Anderson T et al. AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255–2267 (2011).
  • Schwartz GG. New horizons for cholesterol ester transfer protein inhibitors. Curr. Atheroscler. Rep. 14(1), 41–48 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.